Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Change in Accured Expenses (2016 - 2026)

Viridian Therapeutics, Inc.\DE has reported Change in Accured Expenses over the past 12 years, most recently at $21.3 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $21.3 million for Q4 2025, up 97.5% from a year ago — trailing twelve months through Dec 2025 was $16.2 million (down 24.04% YoY), and the annual figure for FY2025 was $16.2 million, down 24.04%.
  • Change in Accured Expenses for Q4 2025 was $21.3 million at Viridian Therapeutics, Inc.\DE, up from $4.6 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for VRDN hit a ceiling of $21.3 million in Q4 2025 and a floor of -$15.8 million in Q1 2025.
  • Median Change in Accured Expenses over the past 5 years was $2.9 million (2021), compared with a mean of $2.6 million.
  • Biggest five-year swings in Change in Accured Expenses: skyrocketed 1610.78% in 2021 and later plummeted 1671.03% in 2025.
  • Viridian Therapeutics, Inc.\DE's Change in Accured Expenses stood at $1.6 million in 2021, then soared by 269.25% to $6.0 million in 2022, then decreased by 24.48% to $4.5 million in 2023, then skyrocketed by 138.05% to $10.8 million in 2024, then skyrocketed by 97.5% to $21.3 million in 2025.
  • The last three reported values for Change in Accured Expenses were $21.3 million (Q4 2025), $4.6 million (Q3 2025), and $6.1 million (Q2 2025) per Business Quant data.